16,16-Bis(furan-3-yl)-2-azoniatetracyclo[6.6.2.02,7.09,14]hexadeca-2,4,6,9,11,13-hexaene;chloride

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: 16,16-Bis(furan-3-yl)-2-azoniatetracyclo[6.6.2.02,7.09,14]hexadeca-2,4,6,9,11,13-hexaene;chloride
• 化学式: C23H18ClNO2
• 分子量: 375.8
• InChiKey: DPLDNNYIQKQVGL-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  1.59
• 重原子数：
  27
• 可旋转键数：
  2
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  30.2
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• MULTI-CYCLIC COMPOUNDS
  申请人：KIMURA Teiji

  公开号：US20090062529A1

  公开（公告）日：2009-03-05

  A compound represented by the formula (I): or a pharmacologically acceptable salt thereof, wherein Ar 1 represents an imidazolyl group or the like which may be substituted with a C1-6 alkyl group, Ar 2 represents a phenyl group or the like which may be substituted with a C1-6 alkoxy group, X 1 represents a double bond or the like and Het represents a triazolyl group or the like which may be substituted with a C1-6 alkyl group or the like, is effective as a therapeutic or prophylactic agent for a disease caused by Aβ.

  一种由化学式(I)表示的化合物或其药理学可接受的盐，其中Ar1代表可用C1-6烷基基团取代的咪唑基团或类似基团，Ar2代表可用C1-6烷氧基团取代的苯基团或类似基团，X1代表双键或类似基团，Het代表可用C1-6烷基基团或类似基团取代的三唑基团或类似基团，对由Aβ引起的疾病具有治疗或预防作用。
• Nitrogen-Containing Fused Heterocyclic Compounds and Their use as Beta Amyloid Production Inhibitors
  申请人：Kitazawa Noritaka

  公开号：US20120053171A1

  公开（公告）日：2012-03-01

  A compound represented by the formula [I]: or a pharmacologically acceptable salt or ester thereof, wherein Ring A represents a five-membered aromatic heterocyclic group or the like fused with a non-aromatic ring group, which may be substituted, Ring B represents a phenyl group or the like which may be substituted, X1 represents a single bond or the like, R1 and R2 each represent a C1-6 alkyl group or the like, m represents an integer of 0 to 3, and n represents an integer of 0 to 2, is effective as a therapeutic agent for a disease caused by Aβ.

  化合物的化学式为[I]，或其药理学上可接受的盐或酯，其中环A代表一个五元芳香杂环基团或类似物，与非芳香环基团融合，可以被取代，环B代表苯基或类似物，可以被取代，X1代表单键或类似物，R1和R2各代表C1-6烷基或类似物，m代表0至3的整数，n代表0至2的整数，该化合物对由Aβ引起的疾病具有治疗作用。
• IMIDAZOYL PYRIDINE COMPOUNDS AND SALTS THEREOF
  申请人：KIMURA Teiji

  公开号：US20110065696A1

  公开（公告）日：2011-03-17

  A compound represented by the formula (I): or a pharmacologically acceptable salt thereof, wherein Ar 1 represents an imidazolyl group or the like which may be substituted with a C1-6 alkyl group, Ar 2 represents a phenyl group or the like which may be substituted with a C1-6 alkoxy group, X 1 represents a double bond or the like and Het represents a triazolyl group or the like which may be substituted with a C1-6 alkyl group or the like, is effective as a therapeutic or prophylactic agent for a disease caused by Aβ.

  化合物的化学式为(I)或其药理学上可接受的盐，其中Ar1代表咪唑基团或类似基团，该基团可能被C1-6烷基取代，Ar2代表苯基或类似基团，该基团可能被C1-6烷氧基取代，X1代表双键或类似基团，Het代表三唑基团或类似基团，该基团可能被C1-6烷基或类似基团取代，可用作治疗或预防由Aβ引起的疾病的药物。
• POLYCYCLIC COMPOUND
  申请人：Kimura Teiji

  公开号：US20110009619A1

  公开（公告）日：2011-01-13

  Disclosed is a compound represented by the formula (I): or a pharmacologically acceptable salt thereof, which is effective as a therapeutic or prophylactic agent for a disease induced by Aβ, wherein Ar 1 represents an imidazolyl group which may be substituted with a C1-6 alkyl group, or the like; Ar 2 represents a phenyl group which may be substituted with a C1-6 alkoxy group, or the like; X 1 represents a double bond, or the like; and Het represents a triazolyl group or the like which may be substituted with a C1-6 alkyl group or the like, or the like.

  本发明涉及一种化合物，其化学式为(I)：或其药学上可接受的盐，该化合物有效地作为由Aβ引起的疾病的治疗或预防剂。其中，Ar1表示咪唑基，可以用C1-6烷基等取代；Ar2表示苯基，可以用C1-6烷氧基等取代；X1表示双键等；Het表示三唑基等，可以用C1-6烷基等取代。
• THERAPEUTIC AGENT FOR DISEASES ASSOCIATED WITH NERVE AXON DYSFUNCTION, INCLUDING THERAPEUTIC AGENT FOR ALZHEIMER'S DISEASE
  申请人：Resilio Company Limited

  公开号：US20170129915A1

  公开（公告）日：2017-05-11

  Provided are a clinically applicable drug for radical cure of Alzheimer's disease (AD), and a drug for treating neurological diseases associated with axonal dysfunction other than AD, wherein the drug utilizes the mechanism of action of the AD radical cure therapy. The drugs are oral drugs, each comprising one or more compounds selected from diosgenin, a diosgenin derivative and a pharmaceutically acceptable salt thereof, the one or more compounds being suspended in an edible oil.

  提供了一种用于根治阿尔茨海默病（AD）的临床应用药物，以及一种用于治疗与轴突功能障碍相关的神经系统疾病的药物，该药物利用AD根治疗法的作用机制。这些药物是口服药物，每种药物包含一种或多种从薯蓣甙、薯蓣甙衍生物和其药学上可接受的盐中选择的化合物，这些化合物悬浮在可食用油中。